title: Effects of a low, oral dose of nisoldipine on the systemic and coronary hemodynamics and the prostaglandin metabolism of ischemic heart disease patients.
abstract: This study investigated the effects of a low dose of nisoldipine (5 mg, p.o.) in 10 patients with ischemic heart disease. The patients were subjected to a 90-min exercise regimen before and after a 5 mg dose of nisoldipine, using a supine bicycle ergometer adjusted to each patient's limitations. The mean blood plasma level of nisoldipine was 3.8 +/- 3.1 (SD) ng/ml. The drug significantly decreased the systolic arterial pressure in patients throughout the experimental session, whereas a change in the diastolic arterial pressure appeared only at the submaximal stage of the exercise. Additionally, at maximal exercise, nisoldipine caused a decrease in the mean coronary sinus pressure from 11.4 +/- 7 mmHg to 6.5 +/- 5 mmHg (p less than 0.01). By contrast, while at rest, nisoldipine decreased the coronary vascular resistance from 1.5 +/- 0.7 mmHg/ml/min to 1.0 +/- 0.7 mmHg/ml/min (p less than 0.05). After exercise, the drug decreased thromboxane B2 levels from 1133 +/- 907 pg/ml to 720 +/- 379 pg/ml (p less than 0.05) in the coronary sinus blood, and increased the 6 keto-prostaglandin F1 alpha levels from 465 +/- 135 pg/ml to 559 +/- 167 pg/ml (p less than 0.05) in brachial artery blood. This suggests that a low, oral dose of nisoldipine can moderately improve the systemic and coronary hemodynamics and afterloads, and may assist in improving the prostaglandin metabolism in ischemic heart disease patients.
authors.affiliation: Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Kurita
authors.forename: B
authors.initials: B
authors.lastname: Takase
authors.forename: A
authors.initials: A
authors.lastname: Uehata
authors.forename: H
authors.initials: H
authors.lastname: Sugawara
authors.forename: T
authors.initials: T
authors.lastname: Nishioka
authors.forename: T
authors.initials: T
authors.lastname: Maruyama
authors.forename: K
authors.initials: K
authors.lastname: Satomura
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: K
authors.initials: K
authors.lastname: Mizuno
authors.forename: K
authors.initials: K
authors.lastname: Isojima
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005080:Exercise Test; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D015737:Nisoldipine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D011453:Prostaglandins / Q000378:metabolism*; D013929:Thromboxane B2 / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D011453:Prostaglandins; D015737:Nisoldipine; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha